Beaver County last month joined others in a lawsuit against a large group of drug companies and people associated with surging prescribing of narcotics. One pharmaceutical giant, Purdue Pharma, was quick to deny accusations in the lawsuit, stating that it is “deeply troubled by the opioid crisis” and “dedicated to being part of the solution.”
Purdue Pharma, however, has a special role in this story. It brought a close chemical cousin of heroin, oxycodone, to the mass American market for the first time in 1995, under the name OxyContin. It is not only the most powerful and addictive opioid ever produced, it is also the best-selling.
When the drug was introduced, physicians were understandably wary of its risk of abuse, but Purdue assured them that the drug’s delayed-release mechanism would minimize its “habit-forming” potential. The 12-hour coverage also meant patients could sleep through the night — a crucial improvement over the older opioids.
Except for roughly half the population, the effects of OxyContin wear off well before 12 hours. A recent expose by the Los Angeles Times revealed that Purdue’s own internal studies had demonstrated this, but Purdue suppressed those studies before submitting OxyContin to the Food and Drug Administration for approval.
Patrick Radden Keefe’s recent article in The New Yorker advanced the story. “For Purdue, the business reason for obscuring such results was clear: the claim of 12-hour relief was an invaluable marketing tool,” he wrote. “But prescribing a pill on a 12-hour schedule when, for many patients, it works for only eight, is a recipe for withdrawal, addiction and abuse.” Mr. Keefe’s chilling report also shows that Purdue knew exactly where “pill mill” operations were running, but rather than report these doctors to the law, Purdue was all too happy to meet the increased demand.
OxyContin generates $3 billion annually for Purdue to this day — $35 billion over its lifetime. The company is now pushing the drug, through a Purdue-related company called Mundipharma, into Asia, Latin America and the Middle East — just like Big Tobacco did after the truth about its products got out in the U.S.
Solving the opioid crisis will depend partly on understanding the drugs that are out there and how potent they are — and making sure pharmaceutical companies, drug distributors and prescribers treat them like the potentially lethal substances they are.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.